Document Detail

Impact of methylprednisolone treatment on the expression of macrophage inflammatory protein 3alpha and B lymphocyte chemoattractant in serum of multiple sclerosis patients.
MedLine Citation:
PMID:  18799824     Owner:  NLM     Status:  MEDLINE    
In order to extend our studies designed to elucidate the mechanism of action of intravenous methylprednisolone (ivMP) in symptomatic therapy of relapses in multiple sclerosis (MS) victims, we have evaluated the expression of chemokines: macrophage inflammatory protein 3alpha (MIP-3alpha) and B-lymphocyte chemoattractant (CXCL13) before and after treatment. The data from further exploration of the MP mechanism of action in MS relapses may be helpful in establishing the treatment design, that would be specific both for individuals, and for the disease phase. The mean levels of MIP-3alpha in sera of MS patients showed no statistically significant differences compared to control subjects. The comparison of MIP-3alpha level before and after therapy with ivMP gave the same result. The CXCL13 expression in serum was significantly higher in the group of MS patients than in healthy subjects. After therapy with ivMP the estimated level demonstrated an increase as related to the initial values found in MS patients. Such a response was seen also in the responder but not in nonresponder subgroup. The enhancement of CXCL13 expression after iv MP therapy in MS relapses may explain the lack of a long-term effect of MP therapy in MS. The observed difference in CXCL13 expression between responder and non-responder group of patients should be regarded as a step towards elucidation of the therapeutic effect of ivMP in MS relapses.
Grazyna Michałowska-Wender; Jacek Losy; Justyna Biernacka-Łukanty; Mieczysław Wender
Related Documents :
15501994 - Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resista...
25475724 - Prostaglandin d2 synthase related to estrogen in the female reproductive tract.
11986944 - Increased expression of the breast cancer resistance protein (bcrp) in relapsed or refr...
15541024 - All trans-retinoic acid (atra) elevated eukaryotic translation initiation factor 4a1 (e...
24489274 - A5.5 smoc2 modulates chondrogenesis by interfering with wnt and bmp signalling.
15994334 - Activation of nf-kappab by extracellular matrix is involved in spreading and glucose-st...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Pharmacological reports : PR     Volume:  60     ISSN:  1734-1140     ISO Abbreviation:  Pharmacol Rep     Publication Date:    2008 Jul-Aug
Date Detail:
Created Date:  2008-09-18     Completed Date:  2009-01-15     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101234999     Medline TA:  Pharmacol Rep     Country:  Poland    
Other Details:
Languages:  eng     Pagination:  549-54     Citation Subset:  IM    
Neuroimmunological Unit, Medical Research Center, Polish Academy of Sciences, Przybyszewskiego 49, PL 60-355 Poznań, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Case-Control Studies
Chemokine CCL20 / blood*
Chemokine CXCL13 / blood*
Glucocorticoids / administration & dosage,  therapeutic use*
Injections, Intravenous
Methylprednisolone / administration & dosage,  therapeutic use*
Middle Aged
Multiple Sclerosis, Relapsing-Remitting / blood,  drug therapy*
Reg. No./Substance:
0/CCL20 protein, human; 0/CXCL13 protein, human; 0/Chemokine CCL20; 0/Chemokine CXCL13; 0/Glucocorticoids; 83-43-2/Methylprednisolone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Serum and intraerythrocyte antioxidant enzymes and lipid peroxides in children with migraine.
Next Document:  Comparison of the effect of 4-hydroxycoumarin and umbelliferone on the phase transition of dipalmito...